As ever, Merck is playing for the long term wins -- spanning decades perhaps. And it can afford to do so, with the pembrolizumab franchise to contribute over $20 billion a year, through the mid-2030s, now. Here's the latest -- and a bit, from both CEOs:
. . .Merck and Mayo Clinic, the world's top-ranked hospital system, today announced a research and development agreement to apply artificial intelligence (AI), advanced analytics and multimodal clinical data to support drug discovery and development. The agreement integrates Mayo Clinic's Platform architecture as well as clinical and genomic datasets with Merck's ambition to harness AI-enabled virtual cell technologies to enhance disease understanding, improve target identification and drive early development decisions. . . .
"New cutting-edge technologies are enhancing our ability to innovate with the potential to bring important new therapies to patients faster. By working with Mayo Clinic, we aim to integrate high-quality clinical data and AI-enabled insights into discovery research to improve target identification and, ultimately, the probability of success for our programs," said Robert M. Davis, chairman and CEO, Merck.
"By combining Mayo Clinic Platform's de-identified data, clinical expertise and Platform technology with Merck's world-class research and development capabilities, we are poised to speed innovative breakthroughs to patients and redefine drug development," said Gianrico Farrugia, M.D., president and CEO, Mayo Clinic. "This collaboration represents a new present and future for healthcare -- one where platform-based collaboration leads to more answers, more cures and better outcomes for patients worldwide. . . ."
So there's your power alley item of the day, for Wednesday. . . with a lovely 60-ish degree sunny day ahead, here. Excellent!
नमस्ते
No comments:
Post a Comment